The effect of anti-AFP-F(ab)'2 and adriamycin conjugate on transplantable tumors in mice.
Efficacy of the conjugate anti-AFP-F(ab)'2 with adriamycin, anti-AFP-F(ab)'2-adr, against transplantable tumors was studied in mice. The results showed that LD50 of anti-AFP-F(ab)'2-adr in mice was 7.43 mg/kg and that anti-AFP-F(ab)'2-adr in a dose of 1/10-1/5 LD50 could inhibit the growth of transplanted hepatocellular carcinoma. In addition, anti-AFP-F(ab)'2-adr with local application of AFP could markedly inhibit the growth of transplanted Ehrlich ascites cancer. From the above it is suggested that anti-AFP-F(ab)'2-adr can be used to treat hepatic carcinoma with satisfactory results.
Tang
W X
WX
Institute of Liver Disease, Tongji Hospital, Tongji Medical University, Wuhan.
Li
P L
PL
Zhang
W Y
WY
Li
S B
SB
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000628:therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D000922:Immunotoxins / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D000509:alpha-Fetoproteins / Q000276:immunology
D000906:Antibodies; D007140:Immunoglobulin Fab Fragments; D000922:Immunotoxins; D000509:alpha-Fetoproteins; D004317:Doxorubicin